Array Biopharma, Inc. (ARRY) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $6.28 +2.61%
EPS Growth %: -52.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
PGR, FEIM, MMED, More
EPS Growth %: -52.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
PGR, FEIM, MMED, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $19.1 million versus the consensus estimate of $18.51 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ASML Holdings (ASML) Tops Q2 EPS by 59c; offers guidance
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- BofA Securities Upgrades Imperial Brands (IMB:LN) (IMBBY) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
